Dr James Martin speaks to ecancer about his study that he presented at ASH 2024.

This study reveals that breast cancer patients on targeted therapies face higher thrombosis rates in real-world settings than in clinical trials.

It focuses on the role of specific medications, especially CDK 4/6 inhibitors, in increasing thrombotic events.

By analysing a large national database, the research highlights the importance of assessing thrombosis risk and considering preventive measures for high-risk patients, enhancing awareness of these risks in patient counselling.